• 1
    Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-Diammine -1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9:140147.
  • 2
    Calvert AH, Harland SJ, Newell DR, et al. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treatment Reviews 1985; 12(suppl A):5157.
  • 3
    Canetta R., Bragman K., Smaldene L., et al. Carboplatin: current status and future prospects. Cancer Treatment Rev 1988; 15:1732.
  • 4
    Curt GA, Grygiel JJ, Corden BJ, et al. A phase I and pharmacokinetic study of diammine cyclobutane-dicarboxylate platinum (NSC 241240). Cancer Res 1983; 43:44704473.
  • 5
    Koeller JM, Trump DL, Tutsch KD, et al. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 1986; 57:222225.
  • 6
    Knox RJ, Friedlos F., Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diammine dichloroplatinum (II) and cis-diammine-(1,1-cyclobutane di-carboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46:19721979.
  • 7
    Siddik ZH, Newell DR, Boxall FE, et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Bio-chem Pharm 1987; 36:19251932.
  • 8
    Elferink F., van der Vijgh WJF, Klein I., et al. Pharmacokinetics of carboplatin after IV administration. Cancer Treat Rep 1987; 71:12311237.
  • 9
    Gaver RC, George AM, Deeb G.. In vitro stability, plasma protein binding and blood cell partitioning of 14C-Carboplatin. Cancer Chemother Pharmacol 1987; 20:271276.
  • 10
    Leyvraz S., Ohnuma T., Lassus M., et al. Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin One 1985; 3:13851392.
  • 11
    Tyczkowska K., Page RL, Riviere JE. Determination of carboplatin in canine plasma by liquid chromatography with ultraviolet-visible detection and confirmation by atomic absorption spectroscopy. J Chromatogr 1990; 527:447453.
  • 12
    Gibaldi M., Perrier D.. Pharmacokinetics, 2nd ed. New York : Marcel Dekker, 1982; 409417.
  • 13
    Courant R., Johm F.. Introduction to Calculus and Analysis. New York : Wiley Interscience, 1965; 483.
  • 14
    Searle SR, Speed FM, Milliken GA. Populations marginal means in the linear model: An alternative to least squares means. The American Statistician 1980; 34:216221.
  • 15
    Cox DR, Snell EJ. Analysis of Binary Data, 23rd ed. London : Methuen and Co, 1989; 158161.
  • 16
    Page RL, Thrall DE, Dewhirst MW, et al. Phase I study of melphalan and whole body hyperthermia in dogs with malignant melanoma. Int J Hyperthermia 1991; 7:559566.
  • 17
    Belani CP, Egorin MJ, Abrams JS, et al. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin One 1989; 17:18961902.
  • 18
    Calvert AH, Newell DR, Gumbrell SO, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin One 1989; 17:17481756.